Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jan 4;24(2):991.
doi: 10.3390/ijms24020991.

Recent Advances of Microfluidic Platform for Cell Based Non-Invasive Prenatal Diagnosis

Affiliations
Review

Recent Advances of Microfluidic Platform for Cell Based Non-Invasive Prenatal Diagnosis

Hei-Jen Jou et al. Int J Mol Sci. .

Abstract

The purpose of the present review is to try to highlight recent advances in the application of microfluidic technology on non-invasive prenatal diagnosis (NIPD). The immunoaffinity based microfluidic technology is the most common approach for NIPD, followed by size-based microfluidic methods. Immunoaffinity microfluidic methods can enrich and isolate circulating fetal extravillous trophoblasts (fEVTs) or fetal nucleated red blood cells (fnRBCs) for NIPD by using specific antibodies, but size-based microfluidic systems are only applied to isolate fEVTs. Most studies based on the immunoaffinity microfluidic system gave good results. Enough fetal cells were obtained for chromosomal and/or genetic analysis in all blood samples. However, the results from studies using size-based microfluidic systems for NIPD are less than ideal. In conclusion, recent advances in microfluidic devices make the immunoaffinity based microfluidic system potentially a powerful tool for cell-based NIPD. However, more clinical validation is needed.

Keywords: circulating fetal cells; extravillous trophoblasts; fetal nucleated RBCs; immunoaffinity; microfluidic devices; non-invasive prenatal diagnosis; size-based microfluidics.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Schematic of laboratory process of NIPD based on microfluidic technology. formula image: antibody; formula image: biotin; formula image: streptavidin; LCM: laser capture microdissection.

References

    1. Morris J.K., Mutton D.E., Alberman E. Revised estimates of the maternal age specific live birth prevalence of Down’s syndrome. J. Med. Screen. 2002;9:2–6. doi: 10.1136/jms.9.1.2. - DOI - PubMed
    1. ACOG Committee on Practice Bulletins ACOG Practice Bulletin No. 77: Screening for fetal chromosomal abnormalities. Obstet. Gynecol. 2007;109:217–227. doi: 10.1097/00006250-200701000-00054. - DOI - PubMed
    1. Nicolaides K.H., Azar G., Byrne D., Mansur C., Marks K. Fetal nuchal translucency: Ultrasound screening for chromosomal defects in first trimester of pregnancy. Br. Med. J. 1992;304:867–869. doi: 10.1136/bmj.304.6831.867. - DOI - PMC - PubMed
    1. Santorum M., Wright D., Syngelaki A., Karagioti N., Nicolaides K.H. Accuracy of first-trimester combined test in screening for trisomies 21, 18 and 13. Ultrasound Obstet. Gynecol. 2017;49:714–720. doi: 10.1002/uog.17283. - DOI - PubMed
    1. Lo Y.M., Corbetta N., Chamberlain P.F., Rai V., Sargent I.L., Redman C.W., Wainscoat J.S. Presence of fetal DNA in maternal plasma and serum. Lancet. 1997;350:485–487. doi: 10.1016/S0140-6736(97)02174-0. - DOI - PubMed